These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
236 related articles for article (PubMed ID: 35313965)
21. High-parametric evaluation of human invariant natural killer T cells to delineate heterogeneity in allo- and autoimmunity. Erkers T; Xie BJ; Kenyon LJ; Smith B; Rieck M; Jensen KP; Ji X; Basina M; Strober S; Negrin RS; Maecker HT; Meyer EH Blood; 2020 Mar; 135(11):814-825. PubMed ID: 31935280 [TBL] [Abstract][Full Text] [Related]
22. Purification and Expansion of Mouse Invariant Natural Killer T Cells for in vitro and in vivo Studies. Delfanti G; Perini A; Zappa E; Fedeli M J Vis Exp; 2021 Feb; (168):. PubMed ID: 33645564 [TBL] [Abstract][Full Text] [Related]
23. A New iNKT-Cell Agonist-Adjuvanted SARS-CoV-2 Subunit Vaccine Elicits Robust Neutralizing Antibody Responses. Li YQ; Yan C; Wang XF; Xian MY; Zou GQ; Gao XF; Luo R; Liu Z ACS Infect Dis; 2022 Oct; 8(10):2161-2170. PubMed ID: 36043698 [TBL] [Abstract][Full Text] [Related]
24. TCR-engineered iNKT cells induce robust antitumor response by dual targeting cancer and suppressive myeloid cells. Delfanti G; Cortesi F; Perini A; Antonini G; Azzimonti L; de Lalla C; Garavaglia C; Squadrito ML; Fedeli M; Consonni M; Sesana S; Re F; Shen H; Dellabona P; Casorati G Sci Immunol; 2022 Aug; 7(74):eabn6563. PubMed ID: 35984893 [TBL] [Abstract][Full Text] [Related]
25. Adoptive therapy by transfusing expanded donor murine natural killer T cells can suppress acute graft-versus-host disease in allogeneic bone marrow transplantation. Yang J; Gao L; Liu Y; Ren Y; Xie R; Fan H; Qian K Transfusion; 2010 Feb; 50(2):407-17. PubMed ID: 19788510 [TBL] [Abstract][Full Text] [Related]
26. Decrease of spleen invariant natural killer T and natural killer cell numbers in Burkholderia thailandensis-infected C57BL/6 mice. Kasetthat T; Sermswan RW; Ren Y; Watarai H; Wongratanacheewin S Asian Pac J Allergy Immunol; 2022 Jun; 40(2):155-161. PubMed ID: 31586487 [TBL] [Abstract][Full Text] [Related]
27. Impact of SARS-CoV-2 in Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy Recipients. Mushtaq MU; Shahzad M; Chaudhary SG; Luder M; Ahmed N; Abdelhakim H; Bansal R; Balusu R; DeJarnette S; Divine C; Kribs R; Shune L; Singh AK; Ganguly S; Abhyankar SH; McGuirk JP Transplant Cell Ther; 2021 Sep; 27(9):796.e1-796.e7. PubMed ID: 34256172 [TBL] [Abstract][Full Text] [Related]
29. Comparison of Different Cytokine Conditions Reveals Resveratrol as a New Molecule for Ex Vivo Cultivation of Cord Blood-Derived Hematopoietic Stem Cells. Heinz N; Ehrnström B; Schambach A; Schwarzer A; Modlich U; Schiedlmeier B Stem Cells Transl Med; 2015 Sep; 4(9):1064-72. PubMed ID: 26160960 [TBL] [Abstract][Full Text] [Related]
32. Potent NKT cell ligands overcome SARS-CoV-2 immune evasion to mitigate viral pathogenesis in mouse models. Lu H; Liu Z; Deng X; Chen S; Zhou R; Zhao R; Parandaman R; Thind A; Henley J; Tian L; Yu J; Comai L; Feng P; Yuan W PLoS Pathog; 2023 Mar; 19(3):e1011240. PubMed ID: 36961850 [TBL] [Abstract][Full Text] [Related]
33. Regadenoson for the treatment of COVID-19: A five case clinical series and mouse studies. Rabin J; Zhao Y; Mostafa E; Al-Suqi M; Fleischmann E; Conaway MR; Mann BJ; Chhabra P; Brayman KL; Krupnick A; Linden J; Lau CL PLoS One; 2023; 18(8):e0288920. PubMed ID: 37566593 [TBL] [Abstract][Full Text] [Related]
34. Adoptive Transfer of Autologous Invariant Natural Killer T Cells as Immunotherapy for Advanced Hepatocellular Carcinoma: A Phase I Clinical Trial. Gao Y; Guo J; Bao X; Xiong F; Ma Y; Tan B; Yu L; Zhao Y; Lu J Oncologist; 2021 Nov; 26(11):e1919-e1930. PubMed ID: 34255901 [TBL] [Abstract][Full Text] [Related]
35. Invariant natural killer T cells: innate-like T cells with potent immunomodulatory activities. Wu L; Gabriel CL; Parekh VV; Van Kaer L Tissue Antigens; 2009 Jun; 73(6):535-45. PubMed ID: 19392798 [TBL] [Abstract][Full Text] [Related]
36. invariant Natural Killer T cell therapy as a novel therapeutic approach in hematological malignancies. Boonchalermvichian C; Yan H; Gupta B; Rubin A; Baker J; Negrin RS Front Transplant; 2024; 3():1353803. PubMed ID: 38993780 [TBL] [Abstract][Full Text] [Related]
37. Risk factors and characteristics influencing humoral response to COVID-19 vaccination in patients after allogeneic stem cell transplantation. Hütter-Krönke ML; Neagoie A; Blau IW; Wais V; Vuong L; Gantner A; Ahn J; Penack O; Schnell J; Nogai KA; Eberspächer B; Saadati M; Benner A; Bullinger L; Döhner H; Bunjes D; Sala E Front Immunol; 2023; 14():1174289. PubMed ID: 37207199 [TBL] [Abstract][Full Text] [Related]
38. Antigen-Specific T Cells and SARS-CoV-2 Infection: Current Approaches and Future Possibilities. Nova Z; Zemanek T; Botek N Int J Mol Sci; 2022 Dec; 23(23):. PubMed ID: 36499448 [TBL] [Abstract][Full Text] [Related]
39. Functions of CD1d-Restricted Invariant Natural Killer T Cells in Antimicrobial Immunity and Potential Applications for Infection Control. Kinjo Y; Takatsuka S; Kitano N; Kawakubo S; Abe M; Ueno K; Miyazaki Y Front Immunol; 2018; 9():1266. PubMed ID: 29928278 [TBL] [Abstract][Full Text] [Related]
40. Inflammatory mechanisms in sepsis: elevated invariant natural killer T-cell numbers in mouse and their modulatory effect on macrophage function. Heffernan DS; Monaghan SF; Thakkar RK; Tran ML; Chung CS; Gregory SH; Cioffi WG; Ayala A Shock; 2013 Aug; 40(2):122-8. PubMed ID: 23807244 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]